Cost-effectiveness of a cervical screening program with human papillomavirus vaccine

International Journal of Technology Assessment in Health Care

Volumn 27, Issue 4, 2011, Pages 290-297

  Sopina, Elizaveta ^a   Ashton, Toni ^a  

^a UNIVERSITY OF AUCKLAND   (New Zealand)

Author keywords

Cervical cancer; Cervical screening; Cost effectiveness; HPV vaccine

Indexed keywords

CERVICAL CANCERS; CURRENT SCREENING; FREQUENCY INTERVALS; HUMAN PAPILLOMAVIRUS; INCREMENTAL COST; NATURAL HISTORY; NEW ZEALAND; SCREENING PROGRAMS; SCREENING STRATEGY; STATE-TRANSITION MODEL;

COST EFFECTIVENESS; ONCOGENIC VIRUSES; VACCINES;

DIAGNOSIS;

WART VIRUS VACCINE;

ADOLESCENT; ADULT; AGED; ARTICLE; CANCER SCREENING; CARCINOGENESIS; COST EFFECTIVENESS ANALYSIS; FEMALE; HUMAN; NEW ZEALAND; PAPILLOMAVIRUS INFECTION; QUALITY OF LIFE; SENSITIVITY ANALYSIS; UTERINE CERVIX CANCER;

ADOLESCENT; ADULT; AGE FACTORS; AGED; AGED, 80 AND OVER; CHILD; COST-BENEFIT ANALYSIS; FEMALE; HEALTH POLICY; HUMANS; MARKOV CHAINS; MASS SCREENING; MIDDLE AGED; MODELS, ECONOMIC; NEW ZEALAND; PAPILLOMAVIRUS INFECTIONS; PAPILLOMAVIRUS VACCINES; QUALITY-ADJUSTED LIFE YEARS; VAGINAL SMEARS; YOUNG ADULT;

EID: 84858974671     PISSN: 02664623     EISSN: 14716348     Source Type: Journal    
DOI: 10.1017/S0266462311000456     Document Type: Article

References (34)

1. Anderson R, Haas M, Shanahan M. The cost-effectiveness of cervical screening in Australia: What is the impact of screening at different intervals or over a different age range? Aust N Z J Public Health. 2008;32:43-52. (Pubitemid 351351020)
2. Anttila A, Ronco G, Clifford G, et al. Cervical cancer screening programmes and policies in 18 European countries. Br J Cancer. 2004;91:935-941. (Pubitemid 39273788)
3. Ault KA, The Future II Study Group. Effect of prophylactic human papillomavirus L1 virus-like-particle vaccine on risk of cervical intraepithelial neoplasia grade 2, grade 3, and adenocarcinoma in situ: A combined analysis of four randomised clinical trials. Lancet. 2007;369:1861-1868. (Pubitemid 46829356)
4. Australian Institute of Health and Welfare. Cervical screening in Australia 2006-2007. Cancer Series. Canberra: Australian Institute of Health and Welfare; 2009.
5. Brisson M, Van de Velde N, De Wals P, Boily M-C. The potential cost-effectiveness of prophylactic human papillomavirus vaccines in Canada. Vaccine. 2007;25:5399-5408. (Pubitemid 46977529)
6. Canfell K, Barnabas R, Patnick J, Beral V. The predicted effect of changes in cervical screening practice in the UK: Results from a modelling study. Br J Cancer. 2004;91:530-536. (Pubitemid 39093574)
7. Debicki D, Ferko N, Demarteau N, et al. Comparison of detailed and succinct cohort modelling approaches in a multi-regional evaluation of cervical cancer vaccination. Vaccine. 2008;26(Suppl 5):F16-F28.
8. Elbasha E, Dasbach E, Insinga R. A Multi-Type HPV Transmission Model. Bull Math Biol. 2008;70:2126-2176.
9. European Cervical Cancer Screening Network. European guidelines for quality assurance in cervical screening. Luxembourg: Health & Consumer Protection Directorate-General, European Commission; 2003.
10. Goldie SJ, Grima D, Kohli M, et al. A comprehensive natural history model of HPV infection and cervical cancer to estimate the clinical impact of a prophylactic HPV-16/18 vaccine. Int J Cancer. 2003;106:896-904. (Pubitemid 37071668)
11. Goldie SJ, Kohli M, Grima D, et al. Projected clinical benefits and cost-effectiveness of a human papillomavirus 16/18 vaccine. J Natl Cancer Inst. 2004;96:604-615. (Pubitemid 38584984)
12. Hillemanns P, Petry K, Largeron N, et al. Cost-effectiveness of a tetravalent human papillomavirus vaccine in Germany. J Public Health. 2008;17:77-86.
13. Insinga R, Dasbach E, Elbasha E. Epidemiologic natural history and clinical management of Human Papillomavirus (HPV) Disease: A critical and systematic review of the literature in the development of an HPV dynamic transmission model. BMC Infect Dis. 2009;9:119.
14. Joura EA, Leodolter S, Hernandez-Avila M, et al. Efficacy of a quadrivalent prophylactic human papillomavirus (types 6, 11, 16, and 18) L1 virus-like-particle vaccine against high-grade vulval and vaginal lesions: A combined analysis of three randomised clinical trials. Lancet. 2007;369:1693-1702. (Pubitemid 46783792)
15. Kim JJ, Wright TC, Goldie SJ. Cost-effectiveness of alternative triage strategies for atypical squamous cells of undetermined significance. JAMA. 2002;287:2382-2390. (Pubitemid 34493201)
16. Koulova A, Tsui J, Irwin K, et al. Country recommendations on the inclusion of HPV vaccines in national immunization programmes among high-income countries, June 2006-January 2008. Vaccine. 2008;26:6529-6541.
17. Kulasingam S, Connelly L, Conway E, et al. A costeffectiveness analysis of adding a human papillomavirus vaccine to the Australian National Cervical Cancer Screening Program. Sex Health. 2007;4:165-175. (Pubitemid 47339645)
18. Linos A, Riza E. Comparisons of cervical cancer screening programmes in the European Union. Eur J Cancer. 2000;36:2260-2265.
19. Mandelblatt JS, Lawrence WF, Gaffikin L, et al. Costs and benefits of different strategies to screen for cervical cancer in less-developed countries. J Natl Cancer Inst. 2002;94:1469-1483. (Pubitemid 35243745)
20. Maxwell GL, Carlson JW, Ochoa M, et al. Costs and effectiveness of alternative strategies for cervical cancer screening in military beneficiaries. Obstet Gynecol. 2002;100:740-748. (Pubitemid 35300032)
21. Ministry of Health. Cancer: New registrations and deaths 2005. Wellington: Ministry of Health; 2008.
22. Ministry of Health, HPV Project Team. The HPV (Human Papillomavirus) Immunisation Programme. National implementation strategic overview. Wellington: Ministry of Health; 2008.
23. Muñoz N, Castellsagué X, de González AB, Gissmann L. Chapter 1: HPV in the etiology of human cancer. Vaccine. 2006;24(Suppl 3):S1-S10. (Pubitemid 44293019)
24. Myers ER, McCrory DC, Nanda K, Bastian L, Matchar DB. Mathematical model for the natural history of human papillomavirus infection and cervical carcinogenesis Am J Epidemiol. 2000;151:1158-1171. (Pubitemid 30451948)
25. Newall AT, Beutels P, Wood JG, Edmunds WJ, MacIntyre CR. Cost-effectiveness analyses of human papillomavirus vaccination. Lancet Infect Dis. 2007;7:289-296. (Pubitemid 46414076)
26. Parkin DM, Bray F. Chapter 2: The burden of HPV-related cancers. Vaccine. 2006;24(Suppl 3):S11-S25. (Pubitemid 44404053)
27. Rogoza RM, Ferko N, Bentley J, et al. Optimization of primary and secondary cervical cancer prevention strategies in an era of cervical cancer vaccination: A multi-regional health economic analysis. Vaccine. 2008;26(Suppl 5):F46-F58.
28. Sanders GD, Taira AV. Cost-effectiveness of a potential vaccine for human papillomavirus. Emerg Infect Dis. 2003;9:37-48. (Pubitemid 36110201)
29. Sanders GD, Taira AV. Cost effectiveness of a potential vaccine for human papillomavirus. Emerg Infect Dis. 2003;9:37-48. (Pubitemid 36110201)
30. Schiffman M, Castle PE, Jeronimo J, Rodriguez AC, Wacholder S. Human papillomavirus and cervical cancer. Lancet. 2007;370:890-907. (Pubitemid 47371147)
31. Stratton KR, Durch JS, Lawrence RS. Vaccines for the 21st century a tool for decision making. Washington DC: National Academy Press; 2000.
32. Techakehakij W, Feldman RD. Cost-effectiveness of HPV vaccination comparedwith Pap smear screening on a national scale: A literature review. Vaccine. 2008;26:6258-6265.
33. Van de Velde N, Brisson M, Boily M-C. Modeling human papillomavirus vaccine effectiveness: Quantifying the impact of parameter uncertainty. Am J Epidemiol. 2007;165:762-775. (Pubitemid 46434599)
34. Wheeler CM, Dennis JM. Clinical aspects and epidemiology of HPV infections. Perspectives in medical virology. vol. 8. Philadelphia: Elsevier; 2002:1-29.